A cost‐utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed‐dose therapy in patients aged 12 years or more with uncontrolled asthma
Compared with remaining at the same GINA treatment step with ICS/LABA maintenance plus SABA reliever, ICS/LABAs as SMART is more cost-effective in patients aged 12 years or more with uncontrolled asthma. This is because ICS/LABAs as SMART showed a greater gain in QALYs at lower total treatment costs.
Authors
- Carlos E. Rodríguez‐Martínez (ORCID: https://orcid.org/0000-0003-2560-6693)
- Mónica P. Sossa‐Briceño
- José A. Castro‐Rodríguez (ORCID: https://orcid.org/0000-0002-0708-4281)
Institutions
- Pontificia Universidad Católica de Chile (CL)
- Universidad El Bosque (CO)
- Universidad Nacional de Colombia (CO)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1002/ppul.27328
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.65